A poll released in August found about 69% of surveyed Coloradans who needed hospital care attempted to find out what it would ...
Arvinas focuses on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. Read why we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback